Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb;22(2):158-166.
doi: 10.1111/dom.13884. Epub 2019 Oct 24.

Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study

Linong Ji  1 , Ningling Sun  1 , Yunliang Zhang  2 , Lihui Zhang  3 , Sheng'ai Shen  4 , Xueying Wang  5 , Qiuyun Li  6 , Luling Dong  7 , Weidong Ren  8 , Lin Qi  9 , Yufeng Li  10 , Shuang Yan  11 , Wenli Cheng  12 , Hongyu Kuang  13 , Guangwei Li  14
Affiliations
Randomized Controlled Trial

Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study

Linong Ji et al. Diabetes Obes Metab. 2020 Feb.

Abstract

Aim: To investigate the effectiveness of metformin in delaying or preventing progression to diabetes in a Chinese population with impaired glucose regulation (IGR).

Materials and methods: This multicentre, randomized, open-label, controlled study (NCT03441750) will assess the efficacy of metformin in preventing diabetes over ≥2 years. Eligible participants will be randomly assigned (1:1) to lifestyle intervention (LSI) or metformin plus LSI, with stratification based on blood pressure, anti-hypertensive medication use and isolated/non-isolated impaired fasting glucose. All participants will receive LSI advice. Participants in the metformin plus LSI group will receive metformin 850 mg once daily for the first 2 weeks, and twice daily thereafter, according to tolerability.

Results: The primary objective is to compare rates of newly diagnosed diabetes in the two intervention groups. Changes in glycaemia, blood pressure, body weight, insulin resistance, and safety outcomes will also be evaluated.

Conclusions: This large clinical trial in a Chinese population with IGR aims to provide critical information to guide clinical decision-making in order to alleviate the current diabetes epidemic.

Keywords: diabetes; impaired glucose regulation; lifestyle intervention; metformin; randomized controlled clinical trial.

PubMed Disclaimer

References

REFERENCES

    1. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948-959.
    1. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317:2515-2523.
    1. Buysschaert M, Bergman M. Definition of prediabetes. Med Clin N Am. 2011;95:289-297.
    1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: WHO; 1999. https://apps.who.int/iris/bitstream/handle/10665/66040/WHO_NCD_NCS_99.2.... Accessed May 30, 2019.
    1. Wilson ML. Prediabetes: Beyond the borderline. Nurs Clin North Am. 2017;52:665-677.

Publication types

Associated data